Effect of PPAR agonist treatment on ACO activity and CYP4A content in WT versus PPARα-null mice
| Treatment | PPARα WT | PPARα-Null | ||
|---|---|---|---|---|
| ACO Activity | CYP4A Content | ACO Activity | CYP4A Content | |
| nmol/min/mg (% change) | AU units (% change) | nmol/min/mg (% change) | AU units (% change) | |
| Vehicle | 2.38 ± 0.19 | 0.16 ± 0.03 | 2.69 ± 0.35 | 0.077 ± 0.013 |
| WY14643, 50 mg/kg/day | 43.11 ± 4.573-160 (1713) | 0.43 ± 0.013-160 (165) | 2.65 ± 0.07 (−2) | 0.082 ± 0.006 (6) |
| TZD, 500 mg/kg/day | 10.64 ± 1.343-160 (348) | 0.45 ± 0.043-160 (180) | 6.80 ± 0.483-160 (153) | 0.26 ± 0.023-160 (238) |
| L-783,483, 500 mg/kg/day | 35.04 ± 2.533-160 (1374) | 0.49 ± 0.023-160 (202) | 9.90 ± 1.323-160 (268) | 0.45 ± 0.043-160 (481) |
Mice were treated as indicated for 6 days. All parameters are expressed as mean values (±S.E.). CYP4A values have had an average “no sample” background of 0.10 AU subtracted.
3-150 P ≤ .05;
↵3-160 P ≤ .01. P values were calculated using the appropriate t test (equal or unequal variance) based on F test results.